Further expanding its reach in the oncology market, Novartis has struck a deal to acquire US company, Endocyte, which uses drug conjugation technology to target therapeutics and companion imaging agents for the treatment of cancer for US$2.1 B. Novartis gains a potential first-in-class radioligand therapy, 177Lu-PSMA-617, which is in Phase III clinical development for metastatic castration-resistant prostate cancer. The deal comes a year after Novartis’ US$3.9 B acquisition of Advanced Accelerator Applications that provided Lutathera® (lutetium Lu 177 dotatate).